- SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling
Yuko Nagamura et al, 2021, Cancers CrossRef - Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis
Simona Corso et al, 2018, Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways CrossRef - Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh, 2019, Nature Reviews Clinical Oncology CrossRef - Patient-Derived Xenograft: A More Standard “Avatar” Model in Preclinical Studies of Gastric Cancer
Mingtang Zeng et al, 2022, Frontiers in Oncology CrossRef - cMET Exon 14 Skipping: From the Structure to the Clinic
Nele Van Der Steen et al, 2016, Journal of Thoracic Oncology CrossRef - PLEKHA5 regulates the survival and peritoneal dissemination of diffuse-type gastric carcinoma cells with Met gene amplification
Yuko Nagamura et al, 2021, Oncogenesis CrossRef - Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy
Jin-Soo Kim et al, 2024, International Journal of Molecular Sciences CrossRef - Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer
Xiuli Wu et al, 2022, Bioorganic Chemistry CrossRef - Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns
Xiangyuan Ma et al, 2017, PLOS ONE CrossRef - Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
Fatemeh Moosavi et al, 2021, Critical Reviews in Oncology/Hematology CrossRef - Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors
Hideki Yamaguchi et al, 2022, Cancers CrossRef